FDA approves Boehringer Ingelheim blood clot treatment

Wed, 10/20/2010 - 5:33pm
Mass High Tech: The Journal of New England Technology

The U.S. Food and Drug Administration has approved Pradaxa, a drug developed by Boehringer Ingelheim Corp. to lower the risk of stroke and blood clots in patients with irregular heartbeats.

The Ridgefield, Conn.-based pharmaceutical firm reported a 35 percent reduction in stroke and systemic embolism in patients taking Pradaxa twice daily in 150 mg dosages. The dosage is in addition to patients’ current use of warfarin, the existing treatment for non-valvular atrial fibrillation (AFiB) that was approved in the 1950s and, under names such as coumadin, has served as the only U.S.-available oral anticoagulant.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.